Smith & Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 16,000+ employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4,560 million in 2020. Smith & Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith & Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook. Helping you get CLOSER TO ZERO™ delay in wound healing.1 References: 1) Forlee M, van Zyl L, Louw V, Nel J, Fourie N, Hartley R. A randomised controlled trial to compare the clinical efficacy and acceptability of adjustable intermittent and continuous Negative Pressure Wound Therapy (NPWT) in a new portable NPWT system. Paper presented at: EWMA; 2018; Krakow, Poland.